Latest News and Press Releases

AscellaHealth Awarded on the Financial Times Americas’ Fastest Growing Companies 2025 List!

AscellaHealth Honored as Silver Stevie® Award Winner in 2025 American Business Awards®

AscellaHealth Highlights Rare Disease Capabilities and End-to-End Specialty Pharmaceutical Solutions at World Orphan Drug Congress USA 2025

AscellaHealth Releases Q1 2025 Specialty & Rare Pipeline Digest™ Providing Essential Clinical Drug Updates

Optime Care has expanded partnership with Eton Pharmaceuticals to serve as the SP provider for GALZIN®, an FDA-approved treatment for Wilson Disease.

AscellaHealth Commemorates Rare Disease Day, February 28, by Supporting Patients and Caregivers"

AscellaHealth announces the appointment of two senior leaders: Clayton Edwards, RPh, MBA and Carl T. Bertram, PharmD, MS, MBA

New York, USA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight The cell and gene...

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

2024 Deloitte Technology Fast 500™ Ranks AscellaHealth Number 154 with 753% Revenue Growth